12 stories found
Medical technology firms MicroVision and Profusa have successfully met Nasdaq’s continued listing standards, reversing previous delisting risks. The regulatory compliance updates have stabilized their stock valuations and restored full trading privileges on the exchange.
Five companies—Profusa, Baidu, Amylyx Pharmaceuticals, FreeCast, and Klarna Group—are highlighted as being on investors' radar for various reasons.
HRT Financial has reported the sale of $2,211 worth of shares in Profusa (PFSA).
Profusa has inked a term sheet to merge with a $111 million health diagnostics firm and has appointed Jack Stover as its new CEO.
Biotechnology firm Profusa has officially met the exchange's minimum publicly held shares threshold, resolving previous listing compliance concerns.
HRT Financial LP has sold shares in two companies, Profusa and Maison Solutions. The firm divested $1,234 worth of Profusa shares and $6,103 of Maison Solutions stock.
Profusa has announced its plan to implement a 1-for-4 reverse stock split.
Profusa approved a 1-for-25 reverse stock split, causing its shares to tumble, while Service Properties Trust announced a 5-for-1 reverse split effective July 6, which will reduce its shares by 80%.
Profusa, Flow Cap, and Wi2Wi have each reported their second-quarter financial results. Flow Cap specifically announced a Non-GAAP EPS of $0.06 and revenue of $4.23 million.
HRT Financial LP has divested shares in Profusa and Maison Solutions, with the firm selling $1,234 worth of Profusa shares and $6,103 of Maison Solutions stock.
Profusa is reportedly competing for the potential acquisition of G3 Vision Labs, indicating a move to expand its market presence.
Profusa, a medical technology company, has been granted a transfer to the Nasdaq Capital Market but must meet a compliance deadline in July.